These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 29317165)
41. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents. Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318 [TBL] [Abstract][Full Text] [Related]
42. Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents. Marhadour S; Marchand P; Pagniez F; Bazin MA; Picot C; Lozach O; Ruchaud S; Antoine M; Meijer L; Rachidi N; Le Pape P Eur J Med Chem; 2012 Dec; 58():543-56. PubMed ID: 23164660 [TBL] [Abstract][Full Text] [Related]
43. Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors. Gu W; Dai Y; Qiang H; Shi W; Liao C; Zhao F; Huang W; Qian H Bioorg Chem; 2017 Jun; 72():116-122. PubMed ID: 28411406 [TBL] [Abstract][Full Text] [Related]
44. Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 1,8-naphthyridin-2-one moiety. Tang Q; Duan Y; Xiong H; Chen T; Xiao Z; Wang L; Xiao Y; Huang S; Xiong Y; Zhu W; Gong P; Zheng P Eur J Med Chem; 2018 Oct; 158():201-213. PubMed ID: 30216852 [TBL] [Abstract][Full Text] [Related]
45. Design and synthesis of novel 2-(4-(2-(dimethylamino)ethyl)-4H-1,2,4-triazol-3-yl)pyridines as potential antitumor agents. Qin M; Zhai X; Xie H; Ma J; Lu K; Wang Y; Wang L; Gu Y; Gong P Eur J Med Chem; 2014 Jun; 81():47-58. PubMed ID: 24826815 [TBL] [Abstract][Full Text] [Related]
46. Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors. Megally Abdo NY; Milad Mohareb R; Halim PA Bioorg Chem; 2020 Apr; 97():103667. PubMed ID: 32087416 [TBL] [Abstract][Full Text] [Related]
47. Design, synthesis and pharmacological evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents. Zhou S; Ren J; Liu M; Ren L; Liu Y; Gong P Bioorg Chem; 2014 Dec; 57():30-42. PubMed ID: 25173590 [TBL] [Abstract][Full Text] [Related]
48. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors. Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314 [TBL] [Abstract][Full Text] [Related]
49. Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors. Im D; Jung K; Yang S; Aman W; Hah JM Eur J Med Chem; 2015 Sep; 102():600-10. PubMed ID: 26318067 [TBL] [Abstract][Full Text] [Related]
50. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase. Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306 [TBL] [Abstract][Full Text] [Related]
51. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance. Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884 [TBL] [Abstract][Full Text] [Related]
52. Identification of novel N Qi B; Yang Y; He H; Yue X; Zhou Y; Zhou X; Chen Y; Liu M; Zhang A; Wei F Eur J Med Chem; 2018 Feb; 146():368-380. PubMed ID: 29407963 [TBL] [Abstract][Full Text] [Related]
53. Synthesis and biological evaluation of 4-(2-fluorophenoxy)-3,3'-bipyridine derivatives as potential c-met inhibitors. Zhao S; Zhang Y; Zhou H; Xi S; Zou B; Bao G; Wang L; Wang J; Zeng T; Gong P; Zhai X Eur J Med Chem; 2016 Sep; 120():37-50. PubMed ID: 27187857 [TBL] [Abstract][Full Text] [Related]
54. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia. Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149 [TBL] [Abstract][Full Text] [Related]
55. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity. Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232 [TBL] [Abstract][Full Text] [Related]
56. Design, synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine derivatives as EGFR-TK inhibitors. Abdelgawad MA; Bakr RB; Alkhoja OA; Mohamed WR Bioorg Chem; 2016 Jun; 66():88-96. PubMed ID: 27043178 [TBL] [Abstract][Full Text] [Related]
57. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors. Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461 [TBL] [Abstract][Full Text] [Related]
58. Synthesis of Pyridine and Spiropyridine Derivatives Derived from 2-aminoprop- 1-ene-1,1,3-tricarbonitrile Together with their c-Met Kinase and Antiproliferative Evaluations. Mohareb RM; Abouzied AS; Abbas NS Anticancer Agents Med Chem; 2018 Feb; 17(14):1951-1962. PubMed ID: 28745236 [TBL] [Abstract][Full Text] [Related]